Literature DB >> 8279152

Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

S R Salpeter1.   

Abstract

Isoniazid chemoprophylaxis has long been known to be a highly effective means of preventing silent tuberculous infections from spreading to active disease. There has been much controversy, however, about the risk it carries for fatal hepatotoxicity. In this article I review the rate of fatal isoniazid-induced hepatitis during chemoprophylaxis that is done according to current monitoring guidelines. Information was obtained from a MEDLINE literature search and a survey of tuberculosis control officers in large metropolitan areas throughout the country. Data were included of patients who were monitored according to the American Thoracic Society's guidelines or who were treated after 1983 when the guidelines were published. The pooled results of the published studies showed no hepatotoxic deaths in 20,212 patients in whom prophylaxis was started. The unpublished data showed 2 deaths in 182,285 patients, for a combined rate of 0.001% (2 of 202,497). The death rate for those older than 35 years was estimated to be 0.002% (1 of 43,334). This rate is significantly lower than was previously estimated and should be used to reevaluate the benefit of preventive therapy for tuberculin-reactive patients older than 35. The risk of fatal isoniazid-induced hepatitis is negligible for all ages when patients are routinely monitored for liver toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279152      PMCID: PMC1022345     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  45 in total

1.  Liver enzyme disturbances during isoniazid chemoprophylaxis in children.

Authors:  P H Beaudry; H F Brickman; M B Wise; D MacDougall
Journal:  Am Rev Respir Dis       Date:  1974-11

2.  Isoniazid hepatotoxicity in children.

Authors:  R S Rapp; R W Campbell; J C Howell; E L Kendig
Journal:  Am Rev Respir Dis       Date:  1978-10

3.  Isoniazid liver injury during chemoprophylaxis in children.

Authors:  P Spyridis; C Sinaniotis; I Papadea; L Oreopoulos; S Hadjiyiannis; C Papadatos
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

4.  A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test.

Authors:  J M Fitzgerald; A Gafni
Journal:  Am Rev Respir Dis       Date:  1990-10

5.  Isoniazid hepatitis in adolescents.

Authors:  I F Litt; M I Cohen; H McNamara
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

6.  Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial.

Authors:  S Grzybowski; M J Ashley; G Pinkus
Journal:  Can Med Assoc J       Date:  1976-04-03       Impact factor: 8.262

7.  How safe is isoniazid?

Authors:  J E Thompson
Journal:  Med J Aust       Date:  1978-02-11       Impact factor: 7.738

8.  Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients.

Authors:  P A Thomas; M F Mozes; O Jonasson
Journal:  Arch Surg       Date:  1979-05

9.  Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.

Authors:  R B Byrd; B R Horn; D A Solomon; G A Griggs
Journal:  JAMA       Date:  1979-03-23       Impact factor: 56.272

10.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors:  D E Kopanoff; D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1978-06
View more
  28 in total

1.  Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.

Authors:  P Sadaphal; J Astemborski; N M Graham; L Sheely; M Bonds; A Madison; D Vlahov; D L Thomas; T R Sterling
Journal:  Clin Infect Dis       Date:  2001-10-12       Impact factor: 9.079

2.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

3.  Isoniazid-related fatal hepatitis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1996-11

4.  Isoniazid toxicity in a 5-year-old boy.

Authors:  Michelle Science; Shinya Ito; Ian Kitai
Journal:  CMAJ       Date:  2013-05-13       Impact factor: 8.262

Review 5.  A guide to the management of tuberculosis in patients with chronic liver disease.

Authors:  Radha K Dhiman; Vivek A Saraswat; Harshal Rajekar; Chandrasekhar Reddy; Yogesh K Chawla
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

6.  Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-α agent with a disease-modifying antirheumatic drug?

Authors:  Döndü Üsküdar Cansu; Sabri Güncan; N Şule Yaşar Bilge; Timuçin Kaşifoğlu; Cengiz Korkmaz
Journal:  Eur J Rheumatol       Date:  2014-06-01

Review 7.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

8.  Isoniazid-related fatal hepatitis.

Authors:  P S Millard; T C Wilcosky; S J Reade-Christopher; D J Weber
Journal:  West J Med       Date:  1996-06

9.  Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.

Authors:  Thuy T Trinh; Dien T Han; Emily Bloss; Thai H Le; Tung T Vu; Anh H Mai; Nhung V Nguyen; Long T Nguyen; Sy N Dinh; Sara Whitehead
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-10       Impact factor: 2.184

10.  Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Authors:  Anil Pooran; Helen Booth; Robert F Miller; Geoff Scott; Motasim Badri; Jim F Huggett; Graham Rook; Alimuddin Zumla; Keertan Dheda
Journal:  BMC Pulm Med       Date:  2010-02-22       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.